Suboptimal medication adherence in Parkinson's disease

被引:169
作者
Grosset, KA [1 ]
Bone, I [1 ]
Grosset, DG [1 ]
机构
[1] So Gen Hosp, Dept Neurol, Glasgow G51 4TF, Lanark, Scotland
关键词
Parkinson's disease; suboptimal medication use; quality of life;
D O I
10.1002/mds.20602
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Patients take less medication than prescribed in many disease areas but evidence for suboptimal therapy adherence in Parkinson's disease (PD) is limited. A single-center observational study of antiparkinsonian medication was undertaken using electronic monitoring (MEMS; Aardex, Zug, Switzerland) over 3 months. Of 68 patients approached, 6 declined and 8 dropped out, leaving 54 patients (taking 117 preparations) with available data. Poorer compliance was associated significantly with younger age, with taking more antiparkinsonian tablets per day, with higher depression scores, and with poorer quality of life. Of the 54 evaluable patients, 11 (20%) had average total compliance of under 80% (underusers) and 43 (80%) had average total compliance of over 80% (satisfactory adherence). Underusers had median total compliance of 65% (interquartile range, 37-74) versus 98% (interquartile range, 93-102) in the satisfactory adherence group. Timing compliance (number of doses taken in the correct time interval) was poor in both underusers (median, 11%; interquartile range, 2-20) and those with satisfactory adherence (median, 25%; interquartile range, 11-73). In conclusion, poorer compliance is associated with younger age, depression, and more tablets per day, and one-fifth of PD patients underuse medication. Consideration of drug therapy adherence has implications in the management of PD. (c) 2005 Movement Disorder Society.
引用
收藏
页码:1502 / 1507
页数:6
相关论文
共 49 条
  • [1] Ropinirole for the treatment of early Parkinson's disease
    Adler, CH
    Sethi, KD
    Hauser, RA
    Davis, TL
    Hammerstad, JP
    Bertoni, J
    Taylor, RL
    SanchezRamos, J
    OBrien, CF
    [J]. NEUROLOGY, 1997, 49 (02) : 393 - 399
  • [2] [Anonymous], 1997, Perceptions of health and illness: Current research and applications
  • [3] Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
    Bezard, E
    Brotchie, JM
    Gross, CE
    [J]. NATURE REVIEWS NEUROSCIENCE, 2001, 2 (08) : 577 - 588
  • [4] Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study
    Brooks, DJ
    Sagar, H
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (08) : 1071 - 1079
  • [5] Factors influencing compliance with antiepileptic drug regimes
    Buck, D
    Jacoby, A
    Baker, GA
    Chadwick, DW
    [J]. SEIZURE, 1997, 6 (02) : 87 - 93
  • [6] Chaudhuri KR, 2004, J NEUROL NEUROSUR PS, V75, P516
  • [7] Depression and diabetes -: Impact of depression symptoms on adherence, function, costs
    Ciechanowski, PS
    Katon, WJ
    Russo, JE
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (21) : 3278 - 3285
  • [8] A systematic review of the associations between dose regimens and medication compliance
    Claxton, AJ
    Cramer, J
    Pierce, C
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (08) : 1296 - 1310
  • [9] DOSE FREQUENCY AND DOSE INTERVAL COMPLIANCE WITH MULTIPLE ANTIEPILEPTIC MEDICATIONS DURING A CONTROLLED CLINICAL-TRIAL
    CRAMER, J
    VACHON, L
    DESFORGES, C
    SUSSMAN, NM
    [J]. EPILEPSIA, 1995, 36 (11) : 1111 - 1117
  • [10] A systematic review of adherence with medications for diabetes
    Cramer, JA
    [J]. DIABETES CARE, 2004, 27 (05) : 1218 - 1224